RxDoctor Payments Data

Caridad Iparraguirre, MD

Family Medicine · North Bergen, NJNPI 1700383924

Payments from drug & device makers

$10,622in general payments, 2019–2025

Across 544 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$2K
  • GSK$667
  • Madrigal Pharmaceuticals$666
  • Boehringer Ingelheim$653
  • AstraZeneca$637
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$10,54699%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,622 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$56,228
Medicare patients
137
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$68,117
OzempicSemaglutide61$60,629
EliquisApixaban56$57,559
FarxigaDapagliflozin Propanediol59$57,371
LinzessLinaclotide61$46,912
RybelsusSemaglutide24$38,879
ProliaDenosumab22$37,053
CreonLipase/Protease/Amylase11$29,166
VascepaIcosapent Ethyl54$27,496
TrulicityDulaglutide19$25,959
Synjardy XrEmpagliflozin/Metformin Hcl29$25,775
MounjaroTirzepatide17$21,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,597
Repatha SureclickEvolocumab29$19,570
Trijardy XrEmpaglifloz/Linaglip/Metformin17$17,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr$653$111,771102 claims
Novo NordiskOzempic, Rybelsus$607$99,50885 claims
AbbVieLinzess, Creon$2,001$76,07972 claims
PfizerEliquis$413$57,55956 claims
AstraZenecaFarxiga$637$57,37159 claims
Lilly USA, LLCTrulicity, Mounjaro$522$47,40736 claims
AmgenProlia$1,578$37,05322 claims
GSKTrelegy Ellipta$667$19,59730 claims
BayerKerendia$196$16,89112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in North Bergen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →